| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMOA052985 |
| P698 | PubMed publication ID | 16394300 |
| P2093 | author name string | Helen Q Huang | |
| Robert A Burger | |||
| Shashikant Lele | |||
| Deborah K Armstrong | |||
| Gynecologic Oncology Group | |||
| Joan L Walker | |||
| Lari Wenzel | |||
| Larry J Copeland | |||
| Brian Bundy | |||
| Rebecca Baergen | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| cisplatin | Q412415 | ||
| paclitaxel | Q423762 | ||
| P304 | page(s) | 34-43 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | |
| P478 | volume | 354 |
| Q37079908 | "Conflict-of-interest" and participation in IRB deliberations: an alternative perspective |
| Q51899071 | "Of models and men (or women)"--a brief story of a mathematical model and its influence on the management of ovarian cancer. |
| Q36550812 | "Optimal" cytoreduction for advanced epithelial ovarian cancer: a commentary |
| Q59172548 | "Platinum on the road": Interactions of antitumoral cisplatin with proteins |
| Q47127196 | 14-3-3ζ Overexpression is Associated with Poor Prognosis in Ovarian Cancer. |
| Q50798112 | 7th annual International Conference on Ovarian Cancer. |
| Q35234443 | A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172. |
| Q56517336 | A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron (Peginterferon alfa-2b) and Actimmune (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer |
| Q85179739 | A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer |
| Q87289439 | A Study of Liposomal Formulations to Improve the Delivery of Aquated Cisplatin to a Multidrug Resistant Tumor |
| Q47629735 | A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve |
| Q24647989 | A common allele on chromosome 9 associated with coronary heart disease |
| Q87416739 | A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer |
| Q30418195 | A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group study |
| Q86645764 | A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer |
| Q83052427 | A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma |
| Q35883007 | A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer. |
| Q38272777 | A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer |
| Q33580998 | A current review of targeted therapeutics for ovarian cancer |
| Q49593027 | A fully absorbable biomimetic polymeric micelle loaded with cisplatin as drug carrier for cancer therapy |
| Q28611264 | A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression |
| Q92212378 | A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy |
| Q40331453 | A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer |
| Q35294575 | A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer |
| Q58712023 | A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study |
| Q89172934 | A novel chemotherapeutic protocol for peritoneal metastasis and inhibition of relapse in drug resistant ovarian cancer |
| Q37558633 | A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers |
| Q37387427 | A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis. |
| Q92780353 | A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer |
| Q37650593 | A phase 1/2a, dose-escalation, safety, pharmacokinetic, and preliminary efficacy study of intraperitoneal administration of BC-819 (H19-DTA) in subjects with recurrent ovarian/peritoneal cancer |
| Q89455392 | A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer |
| Q44607992 | A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis |
| Q33786353 | A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer |
| Q37107332 | A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer |
| Q30252871 | A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study |
| Q30299971 | A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study |
| Q33422212 | A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies |
| Q91214839 | A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer |
| Q30371470 | A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynec |
| Q33393909 | A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study |
| Q30418953 | A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic |
| Q34698933 | A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission. |
| Q84923684 | A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study |
| Q36484521 | A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis |
| Q46110704 | A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer |
| Q82173913 | A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study |
| Q36758689 | A pilot study of an exercise & cognitive behavioral therapy intervention for epithelial ovarian cancer patients. |
| Q48082239 | A pilot study of combination intraperitoneal recombinant human endostatin and chemotherapy for refractory malignant ascites secondary to ovarian cancer |
| Q36085545 | A prospective, randomized trial of integrative medicine for women with ovarian cancer |
| Q88047255 | A randomized phase II multicenter trial to explore efficacy of weekly intraperitoneal in comparison with intravenous paclitaxel administered immediately after gastrectomy to the patients with high risk of peritoneal recurrence: final results of the |
| Q80146202 | A relevant historical perspective on the current toxicity of IP chemotherapy: implications for the future |
| Q38644521 | A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity - CLEOPATRA and PENELOPE. |
| Q37832934 | A review of cost-effectiveness studies in ovarian cancer |
| Q37589224 | A review of the current evidence for maintenance therapy in ovarian cancer |
| Q28087206 | A systematic review of ovarian cancer and fear of recurrence |
| Q36665886 | A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma |
| Q35941981 | A terrible beauty: a physician's story of ovarian cancer. |
| Q34214323 | AAV-mediated human PEDF inhibits tumor growth and metastasis in murine colorectal peritoneal carcinomatosis model |
| Q37374843 | AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer. |
| Q35564007 | Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer |
| Q26772268 | Abdominal metastases from colorectal cancer: intraperitoneal therapy |
| Q33489414 | Accuracy and complexities of using automated clinical data for capturing chemotherapy administrations: implications for future research |
| Q37670385 | Achievements and unmet needs in the management of advanced ovarian cancer |
| Q58572666 | Aclidinium inhibits proliferation and metastasis of ovarian cancer SKOV3 cells via downregulating PI3K/AKT/mTOR signaling pathway |
| Q34996489 | Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer |
| Q44686824 | Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience. |
| Q37699362 | Acute leukemia in women |
| Q38492121 | Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials |
| Q89094825 | Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial |
| Q36131866 | Adjuvant bidirectional chemotherapy using an intraperitoneal port |
| Q42127606 | Adjuvant bidirectional chemotherapy with intraperitoneal pemetrexed combined with intravenous Cisplatin for diffuse malignant peritoneal mesothelioma |
| Q46113080 | Adjuvant chemotherapy for the "oldest old" ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population? |
| Q36424256 | Adjuvant combined systemic chemotherapy and intraperitoneal chemotherapy for locally advanced gastric cancer |
| Q47795778 | Adjuvant intraperitoneal chemotherapy for the treatment of colorectal cancer at risk for peritoneal carcinomatosis: a systematic review. |
| Q34257201 | Adnexal masses and malignancies of importance to the colorectal surgeon |
| Q54047420 | Advanced Primary Epithelial Ovarian and Peritoneal Carcinoma-Does Diagnostic Accuracy of Preoperative CT Scan for Detection of Peritoneal Metastatic Sites Reflect into Prediction of Suboptimal Debulking? A Prospective Study. |
| Q27852053 | Advanced ovarian cancer: what should be the standard of care? |
| Q40025780 | Aggressive and complex surgery for advanced ovarian cancer: an economic analysis |
| Q43239379 | Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer |
| Q84943384 | An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT) |
| Q52582442 | An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides. |
| Q44044542 | An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer |
| Q38881168 | An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis. |
| Q33787214 | Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer |
| Q41700790 | Analysis of pO2 in Malignant Ascites of Patients with Peritoneal Dissemination of Gastric Cancer |
| Q92617804 | Animal models of colorectal peritoneal metastasis |
| Q34023497 | Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. |
| Q37945089 | Anti-angiogenic agents in ovarian cancer: dawn of a new era? |
| Q38257830 | Anti-angiogenic therapy versus dose-dense paclitaxel therapy for frontline treatment of epithelial ovarian cancer: review of phase III randomized clinical trials |
| Q37351988 | Anti-idiotypic antibody abagovomab in advanced ovarian cancer |
| Q39611397 | Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model. |
| Q33572395 | Antiangiogenic Treatment in Ovarian Cancer in the Era of Evidenced-Based Medicine |
| Q52595302 | Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model. |
| Q35138497 | Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: a case report and review of the literature |
| Q38298318 | Antitumor activity of 4-(N-hydroxyphenyl)retinamide conjugated with poly(L-glutamic acid) against ovarian cancer xenografts |
| Q39377073 | Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination |
| Q33402863 | Antitumor effectiveness and toxicity of cisplatin-loaded long-circulating and pH-sensitive liposomes against Ehrlich ascitic tumor |
| Q100692408 | Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer |
| Q93000443 | Assessing recurrence risk following intraperitoneal chemotherapy for ovarian cancer: A day late and a dollar short? |
| Q30434513 | Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials |
| Q30417640 | Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study |
| Q40920564 | Association Between Preoperative Chemotherapy and Postoperative Complications in Patients Undergoing Surgery for Ovarian Cancer. |
| Q35691922 | Associations with worry about dying and hopelessness in ambulatory ovarian cancer patients |
| Q33930609 | Attenuated Listeria monocytogenes reprograms M2-polarized tumor-associated macrophages in ovarian cancer leading to iNOS-mediated tumor cell lysis. |
| Q52584568 | Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance. |
| Q38644661 | BRCA mutation in ovarian cancer: testing, implications and treatment considerations |
| Q47134293 | BRCA mutations in the manifestation and treatment of ovarian cancer |
| Q53189566 | BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. |
| Q36747377 | BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study |
| Q62112707 | BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer |
| Q39782817 | Bevacizumab and its use in epithelial ovarian cancer |
| Q36567390 | Bevacizumab and ovarian cancer |
| Q38081238 | Bevacizumab as front-line treatment for newly diagnosed epithelial cancer |
| Q33800676 | Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer. |
| Q90346402 | Bidirectional chemotherapy in patients with gastric cancer and peritoneal metastasis |
| Q89635191 | Bidirectional treatment of peritoneal metastasis with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and systemic chemotherapy: a systematic review |
| Q38865597 | Bik subcellular localization in response to oxidative stress induced by chemotherapy, in Two different breast cancer cell lines and a Non-tumorigenic epithelial cell line |
| Q24303660 | Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation |
| Q41344204 | Biodegradable polymeric micelle-encapsulated doxorubicin suppresses tumor metastasis by killing circulating tumor cells |
| Q44786048 | Biodegradable polymeric micelle-encapsulated quercetin suppresses tumor growth and metastasis in both transgenic zebrafish and mouse models |
| Q47899347 | Bladder erosion by an intraperitoneal chemotherapy catheter resulting in catheter protrusion through the external urethral meatus |
| Q98165145 | Boosting Replication and Penetration of Oncolytic Adenovirus by Paclitaxel Eradicate Peritoneal Metastasis of Gastric Cancer |
| Q53233948 | Both heat and new chemotherapeutic drug dioxadet in hyperthermic intraperitoneal chemoperfusion improved survival in rat ovarian cancer model. |
| Q26776201 | Breakthrough therapy for peritoneal carcinomatosis of gastric cancer: Intraperitoneal chemotherapy with taxanes |
| Q36861592 | Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin |
| Q35284185 | Bypassing the EPR effect with a nanomedicine harboring a sustained-release function allows better tumor control |
| Q34788669 | C terminus of Clostridium perfringens enterotoxin downregulates CLDN4 and sensitizes ovarian cancer cells to Taxol and Carboplatin |
| Q37345899 | CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study |
| Q46392762 | CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy |
| Q80332870 | CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy |
| Q44099206 | CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study |
| Q61443956 | CCNG1 (Cyclin G1) regulation by mutant-P53 via induction of Notch3 expression promotes high-grade serous ovarian cancer (HGSOC) tumorigenesis and progression |
| Q41611914 | CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors. |
| Q37180823 | Cabazitaxel-induced stabilization of microtubules enhances radiosensitivity in ovarian cancer cells |
| Q52901387 | Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients |
| Q35765724 | Cancer Stem Cells: From Bench to Bedside |
| Q41266914 | Cancer of the ovary, fallopian tube, and peritoneum |
| Q85015064 | Cancer of the ovary, fallopian tube, and peritoneum |
| Q34729707 | Cancer stem cells-clinical relevance |
| Q37873930 | Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer. |
| Q33413609 | Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial |
| Q50545083 | Care of Pediatric Oncology Patients After Continuous Hyperthermic Peritoneal Perfusion |
| Q34011165 | Cell-penetrating, guanidinium-rich molecular transporters for overcoming efflux-mediated multidrug resistance |
| Q38866846 | Cellular therapy in combination with cytokines improves survival in a xenograft mouse model of ovarian cancer |
| Q79926041 | Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis |
| Q35220006 | Cerebral edema in a patient following cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemoperfusion |
| Q55366217 | Changes in ovarian cancer survival during the 20 years before the era of targeted therapy. |
| Q36088636 | Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer |
| Q39618865 | Characterization of two independent, exposure-time dependent paclitaxel-resistant human ovarian carcinoma cell lines |
| Q26768402 | Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy |
| Q37445609 | Chemotherapy for ovarian cancer in the older adult |
| Q26771397 | Chemotherapy of ovarian cancer in elderly patients |
| Q33724835 | Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy: a Southwest Oncology Group Study |
| Q83955877 | Chemotherapy: Current drugs still have potential in advanced ovarian cancer |
| Q86476741 | Chemotherapy: Limited use of the intraperitoneal route for ovarian cancer-why? |
| Q26738517 | Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies |
| Q38616195 | Circulating tumor cells as trigger to hematogenous spreads and potential biomarkers to predict the prognosis in ovarian cancer. |
| Q84336127 | Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer |
| Q37327524 | Cisplatin induces stemness in ovarian cancer |
| Q37029841 | Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center |
| Q34942127 | Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis |
| Q35756974 | Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin |
| Q92798253 | Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer |
| Q34576852 | Clinical course of patients treated for advanced ovarian carcinoma without surgical intervention |
| Q27024235 | Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer |
| Q37679904 | Clinical response in patients with ovarian cancer treated with metronomic chemotherapy |
| Q47849422 | Clinical studies in CRS and HIPEC: Trials, tribulations, and future directions-A systematic review. |
| Q37937858 | Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer |
| Q34510070 | Clinical trials and progress with paclitaxel in ovarian cancer |
| Q36171268 | Clinical utility of targeted treatments in the management of epithelial ovarian cancer |
| Q47642768 | Co-Delivery of Drugs and Genes Using Polymeric Nanoparticles for Synergistic Cancer Therapeutic Effects |
| Q33728822 | Colonic stenosis caused by infection of an intraperitoneal access port system: a rare complication of intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis |
| Q49787658 | Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential |
| Q50353096 | Combretastatin A4-β-Galactosyl Conjugates for Ovarian Cancer Prodrug Monotherapy. |
| Q34114881 | Commentary: when it comes to chemotherapy, location matters |
| Q27851688 | Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study |
| Q33774527 | Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer |
| Q35793038 | Comparative effectiveness research in gynecologic oncology |
| Q33249818 | Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients |
| Q90736221 | Comparing Paclitaxel-Carboplatin with Paclitaxel-Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer |
| Q33158720 | Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting |
| Q34510371 | Comparison of hyperthermia and adrenaline to enhance the intratumoral accumulation of cisplatin in a murine model of peritoneal carcinomatosis |
| Q30415018 | Comparison of methods to estimate health state utilities for ovarian cancer using quality of life data: a Gynecologic Oncology Group study |
| Q37638386 | Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review |
| Q43230496 | Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications. |
| Q46583746 | Computer simulations of osmotic ultrafiltration and small-solute transport in peritoneal dialysis: a spatially distributed approach. |
| Q91823528 | Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial |
| Q37036787 | Consensus in controversy: The modified Delphi method applied to Gynecologic Oncology practice. |
| Q38063818 | Considerations in the surgical management of ovarian cancer in the elderly |
| Q45423656 | Considerations regarding the administration of systemic therapy for elderly patients with ovarian cancer |
| Q33419612 | Consolidation hyperthermic intraperitoneal chemotherapy and maintenance chemotherapy following laparoscopic cytoreductive surgery in the treatment of ovarian carcinoma |
| Q35154140 | Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer |
| Q37408652 | Consolidation strategies in ovarian cancer: observations for future clinical trials |
| Q37617608 | Contemporary considerations for neoadjuvant chemotherapy in primary ovarian cancer |
| Q38279587 | Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival |
| Q36067725 | Contemporary quality of life issues affecting gynecologic cancer survivors |
| Q38743786 | Contributions of the Japanese Gynecologic Oncology Group (JGOG) in Improving the Quality of Life in Women With Gynecological Malignancies |
| Q39096119 | Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready? |
| Q35642068 | Conversion of a gastric band into an intraperitoneal port in a patient with optimally debulked stage 3C serous ovarian carcinoma. |
| Q41422131 | Conversion therapy for pancreatic cancer with peritoneal metastases using intravenous and intraperitoneal paclitaxel with S-1. |
| Q37582390 | Conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy |
| Q53078546 | Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study. |
| Q42946330 | Correlation of extreme drug resistant assay results and progression-free survival following intraperitoneal chemotherapy for advanced ovarian cancer |
| Q35662929 | Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review. |
| Q30438803 | Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study |
| Q46919795 | Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer |
| Q100503056 | Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer |
| Q79831442 | Critical thinking: an essential role in both the conduct and interpretation of gynecologic cancer clinical research |
| Q37676502 | Culture models to define key mediators of cancer matrix remodeling |
| Q38751236 | Current and emerging treatment options in the management of advanced ovarian cancer |
| Q37832932 | Current and future directions of clinical trials for ovarian cancer |
| Q35100951 | Current state of biomarker development for clinical application in epithelial ovarian cancer |
| Q27028117 | Current status and evolution of preclinical drug development models of epithelial ovarian cancer |
| Q38769834 | Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer |
| Q99726592 | Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States |
| Q37453118 | Current status on biologic therapies in the treatment of epithelial ovarian cancer |
| Q38711390 | Current status on microRNAs as biomarkers for ovarian cancer |
| Q37724199 | Current treatment and clinical trials in ovarian cancer |
| Q36230481 | Cyclin D1 predicts the prognosis of advanced serous ovarian cancer |
| Q80332139 | Cyclooxygenase inhibition and hyperthermia for the potentiation of the cytotoxic response in ovarian cancer cells |
| Q48306893 | Cytomorphological changes induced by intraperitoneal chemotherapy present important diagnostic pitfalls in peritoneal fluid cytology. |
| Q37683243 | Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases. |
| Q26780342 | Cytoreductive Surgery and HIPEC in the Baltic States: An International Scientific Workshop with Live Surgery |
| Q36160064 | Cytoreductive surgery (SRC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of peritoneal carcinomatosis: Our initial experience and technical details |
| Q43765205 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. |
| Q82879157 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignant disease |
| Q38243089 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent ovarian carcinoma: analysis of 30-day morbidity and mortality. |
| Q50213512 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial and recurrent ovarian carcinoma: a single center experience |
| Q38777716 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer |
| Q44623386 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experience |
| Q39249056 | Cytoreductive surgery and intraoperative administration of paclitaxel-loaded expansile nanoparticles delay tumor recurrence in ovarian carcinoma |
| Q80608554 | Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients |
| Q26768296 | Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future |
| Q35837795 | Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy in the treatment of advanced epithelial ovarian cancer |
| Q38193876 | Cytoreductive surgery for advanced ovarian cancer |
| Q58766386 | Cytoreductive surgery in primary advanced epithelial ovarian cancer |
| Q50794640 | Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up. |
| Q84672419 | Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? |
| Q34039344 | Cytotoxic Effects of Newly Synthesized Palladium(II) Complexes of Diethyldithiocarbamate on Gastrointestinal Cancer Cell Lines. |
| Q37486164 | Decreased ARID1A expression is correlated with chemoresistance in epithelial ovarian cancer |
| Q85014716 | Defining the limits of radical cytoreductive surgery for ovarian cancer |
| Q36682388 | Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction |
| Q36691447 | Depth of colorectal-wall invasion and lymph-node involvement as major outcome factors influencing surgical strategy in patients with advanced and recurrent ovarian cancer with diffuse peritoneal metastases |
| Q79825494 | Descriptions in the peer-reviewed literature of the results of phase 2 chemotherapy trials involving gynecologic malignancies: a call for greater objectivity |
| Q39129084 | Determinants of quality of life in ovarian cancer survivors: a pilot study |
| Q64108949 | Development and Biological Analysis of a Novel Orthotopic Peritoneal Dissemination Mouse Model Generated Using a Pancreatic Ductal Adenocarcinoma Cell Line |
| Q30421664 | Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics |
| Q36128985 | Diagnosis and management of peritoneal metastases from ovarian cancer |
| Q34783824 | Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe |
| Q37098838 | Diagnostic potential of tumor DNA from ovarian cyst fluid |
| Q34557778 | Diaphragmatic surgery during cytoreduction for primary or recurrent epithelial ovarian cancer: a review of the literature |
| Q92958229 | Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients |
| Q37627681 | Diffusion of Intraperitoneal Chemotherapy in Women with Advanced Ovarian Cancer in Community Settings 2003-2008: The Effect of the NCI Clinical Recommendation |
| Q40184563 | Digoxin therapy is not associated with improved survival in epithelial ovarian cancer: A SEER-Medicare database analysis |
| Q36588670 | Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer |
| Q36150390 | Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study |
| Q83163542 | Disseminated cancer cells in the peritoneal cavity: what can we do when we detect them? |
| Q33704050 | Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer |
| Q40507697 | Do Ovarian Cancer Patients with a Family History of Cancer (Suspected BRCA1 or BRCA2 Mutation) Suffer Greater Chemotherapy Toxicity? |
| Q30945812 | Does a standardized preoperative algorithm of clinical data improve outcomes in patients with ovarian cancer? A quality improvement project |
| Q42732567 | Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study |
| Q91086979 | Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study |
| Q83607919 | Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy? |
| Q80594542 | Does intraperitoneal therapy have a role in recurrent ovarian cancer? |
| Q90107776 | Does the method of primary treatment affect the pattern of first recurrence in high-grade serous ovarian cancer? |
| Q36160250 | Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study |
| Q54339920 | Dose Dense Chemotherapy for Front-line Ovarian Cancer Treatment: The Price is Right? |
| Q84574339 | Dose-dense chemotherapy in advanced ovarian cancer |
| Q38076257 | Dose-dense paclitaxel with carboplatin for advanced ovarian cancer: a feasible treatment alternative |
| Q36405668 | Doublet chemotherapy in the elderly patient with ovarian cancer |
| Q33787894 | Drug delivery systems for intraperitoneal therapy |
| Q36402123 | Drug delivery systems for ovarian cancer treatment: a systematic review and meta-analysis of animal studies. |
| Q38183786 | Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer |
| Q52866005 | Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma. |
| Q37223541 | Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials |
| Q55435917 | ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway. |
| Q35967152 | Effect of acetyl-l-carnitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin |
| Q91644735 | Effect of different shielding conditions on the stability of Cisplatin |
| Q37701277 | Effect of targeted silencing of IL-8 on in vitro migration and invasion of SKOV3 ovarian cancer cells |
| Q35100812 | Effective Delivery of PEGylated siRNA-Containing Lipoplexes to Extraperitoneal Tumours following Intraperitoneal Administration. |
| Q33462141 | Effectiveness of plasma treatment on gastric cancer cells. |
| Q37415150 | Effects of carrier on disposition and antitumor activity of intraperitoneal Paclitaxel |
| Q96132947 | Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer |
| Q37023919 | Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging |
| Q53570905 | Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. |
| Q38757677 | Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer |
| Q35889432 | Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients |
| Q39358580 | Efficient inhibition of colorectal peritoneal carcinomatosis by drug loaded micelles in thermosensitive hydrogel composites |
| Q57903790 | Emerging drugs for ovarian cancer |
| Q36564821 | Empirical chemosensitivity testing in a spheroid model of ovarian cancer using a microfluidics-based multiplex platform |
| Q36354776 | Enhanced antitumor effects by docetaxel/LL37-loaded thermosensitive hydrogel nanoparticles in peritoneal carcinomatosis of colorectal cancer. |
| Q37255356 | Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1 |
| Q39300912 | Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrest |
| Q49479651 | Enhancement of cisplatin cytotoxicity by Retigeric acid B involves blocking DNA repair and activating DR5 in prostate cancer cells |
| Q37085878 | Enhancing the efficacy of cisplatin in ovarian cancer treatment - could arsenic have a role. |
| Q36377590 | Enzyme-Instructed Intracellular Molecular Self-Assembly to Boost Activity of Cisplatin against Drug-Resistant Ovarian Cancer Cells |
| Q35620158 | Enzyme-instructed self-assembly: a multistep process for potential cancer therapy |
| Q41279840 | Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth |
| Q61448020 | Epigenetic therapy for ovarian cancer: promise and progress |
| Q37724905 | Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review |
| Q34292286 | Epithelial ovarian cancer: A case report |
| Q34708560 | Epithelial ovarian cancer: An overview |
| Q37763786 | Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting |
| Q84233810 | Establishing evidence for change in ovarian cancer surgery--proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis |
| Q36746267 | Establishment of a novel method to evaluate peritoneal microdissemination and therapeutic effect using luciferase assay |
| Q57058665 | Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology: A Systematic Review and Quantitative Analysis |
| Q92171423 | Evaluation of a Simple and Safe Tumor Drilling Technique to Potentiate the Effect of Intraperitoneal Chemotherapy in the Treatment of Recurrent Epithelial Ovarian, Tubal, and Peritoneal Cancer: A Matched Retrospective Cohort Study |
| Q83170387 | Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma |
| Q39445090 | Evaluation of biosafety and intracellular uptake of Cremophor EL free paclitaxel elastic liposomal formulation |
| Q24170227 | Evaluation of exposures to healthcare personnel from cisplatin during a mock demonstration of intra-operative intraperitoneal chemotherapy administration |
| Q90431035 | Evaluation of non-completion of intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer |
| Q38332434 | Evaluation of the Patient-Generated Subjective Global Assessment (PG-SGA) as a predictor of febrile neutropenia in gynecologic cancer patients receiving combination chemotherapy: a pilot study |
| Q85986175 | Evaluation of the cost of CA-125 measurement, physical exam, and imaging in the diagnosis of recurrent ovarian cancer |
| Q39352701 | Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women |
| Q80593735 | Evidence-based chemotherapy administration in advanced ovarian cancer: an impressive past, a disquieting present and an uncertain future |
| Q26741293 | Evolution of management in peritoneal surface malignancies |
| Q37988243 | Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease. |
| Q47752280 | Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells. |
| Q55313752 | Experience and Expectations of Ovarian Cancer Patients in Australia. |
| Q53486371 | Experimental study of antitumour activity and effects on leukocyte count of intraperitoneal administration and hyperthermic intraperitoneal chemoperfusion (HIPEC) with dioxadet in a rat model of ovarian cancer. |
| Q37408655 | Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer |
| Q91670635 | FF-10832 enables long survival via effective gemcitabine accumulation in a lethal murine peritoneal dissemination model |
| Q33418750 | Factors associated with grade 3 or 4 treatment-related toxicity in women with advanced or recurrent cervical cancer: an exploratory analysis of NRG Oncology/Gynecologic Oncology Group trials 179 and 204. |
| Q39423795 | Factors influencing clinical trial enrollment among ovarian cancer patients |
| Q34440586 | Fatigue, Mood, and Sleep, During Intraperitoneal Chemotherapy: A Pilot Case Control Study |
| Q53234775 | Feasibility and effectiveness of inhaled carboplatin in NSCLC patients. |
| Q92799025 | Feasibility and safety of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy in patients with advanced stage ovarian cancer: a single-center experience |
| Q33396173 | Feasibility of intravenous gemcitabine and an intraperitoneal platinum agent in the treatment of ovarian cancer |
| Q39995266 | Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial |
| Q83268686 | Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206 |
| Q64933860 | Feasibility, Safety, and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastasis: A Registry Study. |
| Q37249312 | Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. |
| Q39192789 | Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions |
| Q37364271 | Fifth annual workshop of cytoreductive surgery for advanced ovarian cancer and peritoneal surface malignancies |
| Q91592026 | Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin |
| Q37937937 | First line therapy: have we made any improvement? |
| Q42933356 | First-Line Chemotherapy for Ovarian Cancer: Inferences From Recent Studies |
| Q38213500 | First-line and maintenance therapy for ovarian cancer: current status and future directions |
| Q37656214 | First-line treatment of advanced ovarian cancer: current research and perspectives. |
| Q57918124 | Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis |
| Q38122265 | Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer |
| Q48138644 | Folate-Targeted Surface-Enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detection of Microscopic Ovarian Cancer |
| Q54950226 | Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis. |
| Q40148378 | Folic acid conjugated nanoliposomes as promising carriers for targeted delivery of bleomycin. |
| Q35683268 | Fractalkine receptor CX(3)CR1 is expressed in epithelial ovarian carcinoma cells and required for motility and adhesion to peritoneal mesothelial cells. |
| Q35961843 | Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysis |
| Q47323988 | Front-line therapy of advanced ovarian cancer: new approaches |
| Q38669746 | Frontline treatment of epithelial ovarian cancer. |
| Q29248201 | Functional activation of mutant p53V172F by platinum analogs in cisplatin-resistant human tumor cells is dependent on serine-20 phosphorylation |
| Q37040827 | Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer |
| Q37179400 | Future directions in the management of epithelial ovarian cancer. |
| Q36962482 | GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012. |
| Q92970072 | GSVD- and tensor GSVD-uncovered patterns of DNA copy-number alterations predict adenocarcinomas survival in general and in response to platinum |
| Q27026303 | Gastric cancer with minimal peritoneal metastasis: is this a sign to give up or to treat more aggressively? |
| Q38746293 | Geldanamycin, an inhibitor of Hsp90, increases paclitaxel-mediated toxicity in ovarian cancer cells through sustained activation of the p38/H2AX axis |
| Q37038537 | Genetic detection of free cancer cells in the peritoneal cavity of the patient with gastric cancer: present status and future perspectives |
| Q46611930 | Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study |
| Q41681690 | Gross Appearance and Curability Are Predictive Factors of a Better Prognosis After Gastrectomy in Gastric Cancer Patients with Metastasis to the Adjacent Peritoneum of the Stomach |
| Q64847268 | Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia |
| Q57903763 | Guidelines in ovarian cancer |
| Q33837836 | Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology |
| Q47614058 | Gynecologic cancer in HIV-infected women: treatment and outcomes in a multi-institutional cohort |
| Q37489792 | Gynecologic tumors: how to communicate imaging results to the surgeon |
| Q92861685 | Gynecological Cancers-the Changing Paradigm |
| Q92081878 | HER2-Specific Targeted Toxin DARPin-LoPE: Immunogenicity and Antitumor Effect on Intraperitoneal Ovarian Cancer Xenograft Model |
| Q104134311 | HIPEC after neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease |
| Q38532422 | HIPEC in ovarian cancer: treatment of a new era or is it the end of the pipeline? |
| Q50788596 | HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome. |
| Q91736879 | Harnessing natural killer cells for the treatment of ovarian cancer |
| Q58773636 | Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer |
| Q39203933 | Helical tomotherapy versus conventional radiation to deliver abdominopelvic radiation |
| Q35867496 | Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer. |
| Q64111448 | High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints |
| Q36623377 | Historical progress in the initial management of ovarian cancer: intraperitoneal chemotherapy |
| Q26783551 | Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer |
| Q26796520 | How to Create Evidence for the Integration of Local and Locoregional Treatments in Future Oncological Treatment Concepts? |
| Q34026088 | Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis |
| Q35869447 | Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors |
| Q35855107 | Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts |
| Q34561445 | Hyperthermic Intra-Thoracic Chemotherapy (HITeC) for the management of recurrent ovarian cancer involving the pleural cavity |
| Q40251231 | Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis. |
| Q92702665 | Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer |
| Q36884415 | Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: Where Do We Go From Here? |
| Q38719149 | Hyperthermic intraperitoneal chemoperfusion as a component of multimodality therapy for ovarian and primary peritoneal cancer. |
| Q36549636 | Hyperthermic intraperitoneal chemoperfusion with high dose oxaliplatin: Influence of perfusion temperature on postoperative outcome and survival |
| Q98174930 | Hyperthermic intraperitoneal chemotherapy (HIPEC): Should we look closer at the microenvironment? |
| Q36582197 | Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancers: is there a role? |
| Q92847043 | Hyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is on |
| Q43114850 | Hyperthermic intraperitoneal chemotherapy for ovarian cancer: is there a role? |
| Q34356395 | Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data |
| Q83256036 | Hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer: A critical need for an evidence-based evaluation |
| Q33405507 | Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study |
| Q34996992 | Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study |
| Q90468404 | IL-33 delays metastatic peritoneal cancer progression inducing an allergic microenvironment |
| Q60949960 | ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression |
| Q45861237 | Icodextrin enhances survival in an intraperitoneal ovarian cancer murine model utilizing gene therapy |
| Q33793240 | Identification and characterization of a spontaneous ovarian carcinoma in Lewis rats |
| Q36625238 | Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer |
| Q91754937 | Identifying and targeting angiogenesis-related microRNAs in ovarian cancer |
| Q37601165 | Imaging CXCR4 signaling with firefly luciferase complementation |
| Q92305209 | Immune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional Approaches |
| Q34557233 | Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization |
| Q39349334 | Immunological Functions of the Omentum |
| Q55436310 | Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center. |
| Q34114876 | Impact of shifting from office- to hospital-based treatment facilities on the administration of intraperitoneal chemotherapy for ovarian cancer |
| Q53058595 | Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer. |
| Q39808404 | Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma |
| Q83733281 | Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm |
| Q57493790 | Improved survival in ovarian cancer, with widening survival gaps of races and socioeconomic status: a period analysis, 1983-2012 |
| Q39293603 | Improving anti-tumor activity with polymeric micelles entrapping paclitaxel in pulmonary carcinoma |
| Q41654060 | Improving paclitaxel pharmacokinetics by using tumor-specific mesoporous silica nanoparticles with intraperitoneal delivery |
| Q54941782 | In Vivo 6-([18F]Fluoroacetamido)-1-hexanoicanilide PET Imaging of Altered Histone Deacetylase Activity in Chemotherapy-Induced Neurotoxicity. |
| Q62598252 | In Vivo Anticancer Activity of a Nontoxic Inert Phenolato Titanium Complex: High Efficacy on Solid Tumors Alone and Combined with Platinum Drugs |
| Q36609813 | In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway. |
| Q51942166 | In vivo determination of diffusive transport parameters in a superfused tissue. |
| Q35082675 | In vivo spectral fluorescence imaging of submillimeter peritoneal cancer implants using a lectin-targeted optical agent |
| Q37540587 | Incidence of and risk factors for postoperative ileus in women undergoing primary staging and debulking for epithelial ovarian carcinoma |
| Q44406504 | Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies |
| Q30975500 | Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer |
| Q44019385 | Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study |
| Q36326939 | Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer |
| Q47109168 | Inflammatory Response and Toxicity After Pressurized IntraPeritoneal Aerosol Chemotherapy. |
| Q37260402 | Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer |
| Q38012447 | Inhaled chemotherapy in lung cancer: future concept of nanomedicine |
| Q33976557 | Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts |
| Q39003793 | Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer. |
| Q39011970 | Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model |
| Q33851035 | Inhibition of notch signaling in combination with Paclitaxel reduces platinum-resistant ovarian tumor growth |
| Q39312964 | Inhibition of nuclear factor-κB enhances the antitumor effect of paclitaxel against gastric cancer with peritoneal dissemination in mice. |
| Q39461620 | Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. |
| Q33867457 | Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer |
| Q36474863 | Integrated care in ovarian cancer “IgV Ovar”: results of a German pilot for higher quality in treatment of ovarian cancer |
| Q93139008 | Integrated multi-omics analysis of genomics, epigenomics, and transcriptomics in ovarian carcinoma |
| Q45863477 | Interferon beta adenoviral gene therapy in a patient with ovarian cancer. |
| Q37101337 | Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer |
| Q37585146 | Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results |
| Q35886105 | Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer. |
| Q92498935 | Intraperitoneal (IP) port cytology after completion of primary therapy for advanced stage ovarian cancer: A novel approach to a "second look" |
| Q38931271 | Intraperitoneal Administration of Neural Stem Cell-Nanoparticle Conjugates Targets Chemotherapy to Ovarian Tumors. |
| Q43629231 | Intraperitoneal Catheter Leads to Prolongation of the Time to Normalization of Serum CA125 Levels |
| Q37807369 | Intraperitoneal Chemotherapy: Why the Fuzz? |
| Q41787258 | Intraperitoneal Paclitaxel is useful as adjuvant chemotherapy for advanced gastric cancer with serosal exposure |
| Q51833127 | Intraperitoneal access via direct puncture is an alternative way to deliver intraperitoneal chemotherapy in ovarian, fallopian tube and primary peritoneal cancer. |
| Q39120205 | Intraperitoneal administration of cisplatin via an in situ cross-linkable hyaluronic acid-based hydrogel for peritoneal dissemination of gastric cancer |
| Q39526281 | Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer |
| Q39332785 | Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center |
| Q88126660 | Intraperitoneal chemotherapy among women in the Medicare population with epithelial ovarian cancer |
| Q79206811 | Intraperitoneal chemotherapy and the NCI clinical announcement |
| Q92640775 | Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer |
| Q37760615 | Intraperitoneal chemotherapy for advanced ovarian and peritoneal cancers in patients following interval debulking surgery or primary cytoreductive surgery: Tom Baker Cancer Centre experience from 2006 to 2009. |
| Q36240461 | Intraperitoneal chemotherapy for epithelial ovarian cancer - single center experience |
| Q38986946 | Intraperitoneal chemotherapy for gastric cancer with peritoneal disease: experience from Singapore and Japan. |
| Q38800565 | Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis |
| Q50951601 | Intraperitoneal chemotherapy for optimally debulked advanced ovarian cancer: a new standard in patient care? |
| Q87720938 | Intraperitoneal chemotherapy for ovarian cancer |
| Q51797268 | Intraperitoneal chemotherapy for ovarian cancer: 2009 goals. |
| Q36995650 | Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates |
| Q33279245 | Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care |
| Q37662806 | Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients |
| Q24186509 | Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer |
| Q24235235 | Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer |
| Q38171356 | Intraperitoneal chemotherapy from Armstrong to HIPEC: challenges and promise |
| Q48830395 | Intraperitoneal chemotherapy hyperthermia (HIPEC) for peritoneal carcinomatosis of ovarian cancer origin by fluid and CO2 recirculation using the closed abdomen technique (PRS-1.0 Combat): A clinical pilot study. |
| Q38213258 | Intraperitoneal chemotherapy in advanced epithelial ovarian cancer: a survey |
| Q36444374 | Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy. |
| Q33269777 | Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses |
| Q37230288 | Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin |
| Q37608431 | Intraperitoneal chemotherapy of ovarian cancer |
| Q42321339 | Intraperitoneal chemotherapy of ovarian cancer by hydrogel depot of paclitaxel nanocrystals |
| Q38156120 | Intraperitoneal chemotherapy: rationale, applications, and limitations |
| Q37202777 | Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer? |
| Q80772900 | Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis |
| Q80098140 | Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel |
| Q35739551 | Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study |
| Q59800743 | Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment |
| Q35826455 | Intraperitoneal delivery of a novel liposome-encapsulated paclitaxel redirects metabolic reprogramming and effectively inhibits cancer stem cells in Taxol(®)-resistant ovarian cancer |
| Q37640704 | Intraperitoneal delivery of paclitaxel by poly(ether-anhydride) microspheres effectively suppresses tumor growth in a murine metastatic ovarian cancer model |
| Q35032664 | Intraperitoneal delivery of platinum with in-situ crosslinkable hyaluronic acid gel for local therapy of ovarian cancer. |
| Q39936525 | Intraperitoneal distribution imaging in ovarian cancer patients |
| Q60958697 | Intraperitoneal doxorubicin achieves access to mesenteric lymph nodes, case series of two patients |
| Q34152694 | Intraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer: rationale and report of early data |
| Q80325049 | Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma |
| Q39030522 | Intraperitoneal paclitaxel induces regression of peritoneal metastasis partly by destruction of peripheral microvessels |
| Q93129744 | Intraperitoneal ports placed at the time of bowel resection for treatment of ovarian cancer: Complications and surgical outcomes |
| Q34789701 | Intraperitoneal therapy for peritoneal cancer |
| Q49118164 | Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence |
| Q87542159 | Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis |
| Q33920800 | Investigational agents in development for the treatment of ovarian cancer |
| Q46519965 | Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer? |
| Q30454100 | It's not just for laparoscopy anymore: use of insufflation under ultrasound and fluoroscopic guidance by Interventional Radiologists for percutaneous placement of intraperitoneal chemotherapy catheters |
| Q57212815 | It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer |
| Q34003396 | Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases |
| Q94460616 | Knockdown of long non-coding RNA HOTAIR reverses cisplatin resistance of ovarian cancer cells through inhibiting miR-138-5p-regulated EZH2 and SIRT1 |
| Q36911440 | Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy |
| Q37206348 | Latest research and treatment of advanced-stage epithelial ovarian cancer |
| Q35758403 | Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. |
| Q33658004 | Lessons learned from imaging mouse ovarian tumors: the route of probe injection makes a difference |
| Q37679609 | Lithium chloride and inhibition of glycogen synthase kinase 3β as a potential therapy for serous ovarian cancer |
| Q37079108 | Locally advanced and metastatic gastric cancer: current management and new treatment developments |
| Q37513298 | Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow? |
| Q46401419 | Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy. |
| Q41012742 | Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC). |
| Q30359356 | Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study |
| Q92137657 | Long-term survival after intraperitoneal chemotherapy with paclitaxel-cisplatin for recurrent primary peritoneal cancer resistant to multiple lines of intravenous chemotherapy |
| Q80303977 | Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy |
| Q26849259 | Looking up: Recent advances in understanding and treating peritoneal carcinomatosis |
| Q47950482 | Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer |
| Q64230115 | MT1JP inhibits tumorigenesis and enhances cisplatin sensitivity of breast cancer cells through competitively binding to miR-24-3p |
| Q36362871 | Macrophage Blockade Using CSF1R Inhibitors Reverses the Vascular Leakage Underlying Malignant Ascites in Late-Stage Epithelial Ovarian Cancer |
| Q37231636 | Magneto-electric nanoparticles to enable field-controlled high-specificity drug delivery to eradicate ovarian cancer cells |
| Q34783070 | Major Advances in the Treatment of Cancer: What does a Non-Oncologist need to know? |
| Q33560967 | Major clinical research advances in gynecologic cancer 2009. |
| Q24562146 | Major clinical research advances in gynecologic cancer in 2013 |
| Q34390899 | Malignant peritoneal mesothelioma. |
| Q33909330 | Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis |
| Q26741755 | Management of relapsed ovarian cancer: a review |
| Q36358324 | Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. |
| Q88015812 | Meigs to modern times: The evolution of debulking surgery in advanced ovarian cancer |
| Q33624518 | Melatonin Reduces Angiogenesis in Serous Papillary Ovarian Carcinoma of Ethanol-Preferring Rats |
| Q37316995 | Metastases of colorectal cancer to the liver and peritoneum: comparison of surgical paradigms |
| Q89184189 | Metastatic gynecologic malignancies: advances in treatment and management |
| Q36802689 | Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma. |
| Q96132805 | MiR-153-5p Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Paclitaxel by Inducing G2M Phase Arrest |
| Q35419057 | Microenvironment and pathogenesis of epithelial ovarian cancer |
| Q34285363 | Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy. |
| Q35872796 | Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy |
| Q87899667 | Modeling treatment outcomes for patients with advanced ovarian cancer: Projected benefits of a test to optimize treatment selection |
| Q35760160 | Molecular approaches to personalizing management of ovarian cancer |
| Q37926477 | Molecular mechanisms of cisplatin resistance |
| Q30369661 | Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling. |
| Q38078400 | Monoclonal antibodies therapies for ovarian cancer |
| Q44401200 | Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. |
| Q35412031 | Morbidity and mortality of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: national cancer institute, Mexico city, Mexico |
| Q80222025 | More on intraperitoneal therapy |
| Q42917880 | Mucinous Adenocarcinoma of the Ovary |
| Q36941095 | Multiple large bowel resections: potential risk factor for anastomotic leak |
| Q38797393 | Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study |
| Q33574144 | Multiscale tumor spatiokinetic model for intraperitoneal therapy |
| Q24672758 | Myosin II co-chaperone general cell UNC-45 overexpression is associated with ovarian cancer, rapid proliferation, and motility |
| Q37590339 | NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies |
| Q51065844 | NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. |
| Q64263658 | Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model |
| Q47165034 | Nanoparticle as a novel tool in hyperthermic intraperitoneal and pressurized intraperitoneal aerosol chemotheprapy to treat patients with peritoneal carcinomatosis. |
| Q34994831 | Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice |
| Q34490603 | Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells |
| Q55435902 | Naringin inhibits ovarian tumor growth by promoting apoptosis: An in vivo study. |
| Q34249959 | Natural history of ovarian cancer |
| Q36840009 | Nausea as a sentinel symptom for cytotoxic chemotherapy effects on the gut-brain axis among women receiving treatment for recurrent ovarian cancer: an exploratory analysis |
| Q36840545 | Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers. |
| Q37390324 | Necrotizing fasciitis after placement of intraperitoneal catheter |
| Q38499574 | Neo-adjuvant chemotherapy does not increase the rate of complete resection and does not significantly reduce the morbidity of Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer. |
| Q53054061 | Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. |
| Q30717971 | Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center |
| Q89469046 | Neoadjuvant chemotherapy for newly diagnosed ovarian cancer: It's all about selection |
| Q33626973 | Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline |
| Q30361070 | Neurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: characteristics associated with toxicity and the effect of substitution with docetaxel: an NRG Oncology/Gynecologic Oncology Group study. |
| Q28082524 | New perspectives on targeted therapy in ovarian cancer |
| Q37837735 | New players in ovarian cancer |
| Q39321451 | New poly(ester-amide) copolymers modified with polyether (PEAE) for anticancer drug encapsulation. |
| Q34121226 | Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q64118673 | Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma |
| Q35669726 | Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4 |
| Q34491211 | Notch signaling in serous ovarian cancer |
| Q33470931 | Novel Intraperitoneal Treatment With Non-Thermal Plasma-Activated Medium Inhibits Metastatic Potential of Ovarian Cancer Cells |
| Q64059344 | Novel Small Molecule MEK Inhibitor URML-3881 Enhances Cisplatin Sensitivity in Clear Cell Ovarian Cancer |
| Q58563268 | Novel Surgical Strategies in the Treatment of Gynecological Malignancies |
| Q38982374 | Novel combination of mitochondrial division inhibitor 1 (mdivi-1) and platinum agents produces synergistic pro-apoptotic effect in drug resistant tumor cells |
| Q33994331 | Novel irreversible small molecule inhibitors of replication protein A display single-agent activity and synergize with cisplatin |
| Q49550401 | OV21/PETROC: A randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer |
| Q37477107 | Office-Based Intraperitoneal Chemotherapy for Ovarian Cancer |
| Q94588298 | Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis |
| Q37448942 | Oncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time |
| Q40064850 | Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer |
| Q36996789 | Operative management of primary epithelial ovarian cancer |
| Q36855245 | Opportunities in immunotherapy of ovarian cancer. |
| Q38941559 | Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy? |
| Q24234923 | Optimal primary surgical treatment for advanced epithelial ovarian cancer |
| Q37803067 | Optimally Debulked Stage III Ovarian Cancer: Intraperitoneal or Intravenous Chemotherapy? |
| Q55135995 | Optimization of drug delivery systems for intraperitoneal therapy to extend the residence time of the chemotherapeutic agent. |
| Q35692141 | Optimizing Liposomal Cisplatin Efficacy through Membrane Composition Manipulations |
| Q44579894 | Optimizing management tools for ovarian cancer improves survival |
| Q90412906 | Outcome of Bowel Resection in Women with Advanced Ovarian Carcinoma |
| Q53408126 | Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer. |
| Q37284434 | Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms |
| Q45209332 | Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution's experience |
| Q38244051 | Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis |
| Q35160147 | Ovarian Cancer Tests and Treatment. |
| Q54105461 | Ovarian cancer |
| Q84605146 | Ovarian cancer |
| Q88195269 | Ovarian cancer |
| Q34010642 | Ovarian cancer (advanced) |
| Q38833508 | Ovarian cancer and the immune system - The role of targeted therapies. |
| Q36433053 | Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper |
| Q34086819 | Ovarian cancer development and metastasis |
| Q44225452 | Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin |
| Q37732629 | Ovarian cancer in the elderly: outcomes with neoadjuvant chemotherapy or primary cytoreduction |
| Q37169893 | Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? |
| Q50801058 | Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. |
| Q38703668 | Ovarian cancer spheroid shrinkage following continuous exposure to cisplatin is a function of spheroid diameter |
| Q26862249 | Ovarian cancer standard of care: are there real alternatives? |
| Q48159781 | Ovarian cancer: a brief historical overview of intraperitoneal trials |
| Q44356847 | Ovarian cancer: a bright future |
| Q36642130 | Ovarian cancer: a focus on management of recurrent disease |
| Q38040628 | Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents. |
| Q38143316 | Ovarian cancer: risk factors, treatment and management |
| Q43119082 | Ovarian carcinomatosis in a dog managed with surgery and intraperitoneal, systemic, and intrapleural chemotherapy utilizing indwelling pleural access ports |
| Q36246203 | Ovarian clear cell carcinoma, outcomes by stage: the MSK experience |
| Q36858404 | Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters |
| Q35603456 | Overexpression of Growth-Related Oncogene-β Is Associated with Tumorigenesis, Metastasis, and Poor Prognosis in Ovarian Cancer |
| Q36773924 | Overexpression of claudin-4 may be involved in endometrial tumorigenesis |
| Q92617945 | Overview of the optimal perioperative intraperitoneal chemotherapy regimens used in current clinical practice |
| Q38225315 | PARP inhibition and synthetic lethality in ovarian cancer |
| Q34436731 | PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse |
| Q45172832 | POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer |
| Q41897007 | Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. |
| Q37565541 | Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations |
| Q39160733 | Paclitaxel nanosuspensions for targeted chemotherapy - nanosuspension preparation, characterization, and use. |
| Q36917778 | Paclitaxel-Loaded Polymersomes for Enhanced Intraperitoneal Chemotherapy |
| Q37435420 | Paclitaxel-loaded polymeric microparticles: quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics |
| Q36945032 | Paclitaxel: a review of adverse toxicities and novel delivery strategies. |
| Q37987902 | Palliative chemotherapy for malignant ascites secondary to ovarian cancer |
| Q36741463 | Pathological complete response following neoadjuvant radiotherapy and intraperitoneal perfusion chemotherapy for recurrent colon carcinoma: A case report and literature review |
| Q27336251 | Patient preferences in advanced or recurrent ovarian cancer |
| Q30411910 | Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study |
| Q47415788 | Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone |
| Q57481603 | Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer |
| Q45367726 | Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer |
| Q84279286 | Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy |
| Q38571120 | Pazopanib in ovarian cancer |
| Q91676659 | Perceptions in the management of colorectal peritoneal metastases: A bi-national survey of colorectal surgeons |
| Q34690528 | Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy |
| Q58766340 | Peritoneal carcinomatosis |
| Q45125749 | Peritoneal carcinomatosis in ovarian cancer. Methods and treatment results |
| Q80336380 | Peritoneal carcinomatosis of colorectal origin: standard of care |
| Q37528436 | Peritoneal carcinomatosis of gastrointestinal origin: natural history and treatment options |
| Q34391112 | Peritoneal carcinosis of ovarian origin. |
| Q38156108 | Peritoneal debulking/intraperitoneal chemotherapy-non-sarcoma |
| Q37139726 | Pharmaceutical management of ovarian cancer : current status |
| Q37406628 | Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients |
| Q37993908 | Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics |
| Q36063487 | Pharmacokinetics of the perioperative use of cancer chemotherapy in peritoneal surface malignancy patients |
| Q39561158 | Pharmacologic downregulation of c-FLIP(L) restores juxtacrine death receptor-mediated apoptosis in cancer cells in a peritoneal carcinomatosis model |
| Q41132998 | Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer |
| Q33392777 | Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer |
| Q33379831 | Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma |
| Q30424227 | Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study |
| Q64066802 | Phase I open-label trial of intraperitoneal paclitaxel in combination with intravenous cisplatin and oral capecitabine in patients with advanced gastric cancer and peritoneal metastases (IPGP study): study protocol |
| Q53453814 | Phase I study of intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin in recurrent ovarian and fallopian tube cancer. |
| Q33932032 | Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer |
| Q35931270 | Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer |
| Q34673869 | Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer |
| Q53249660 | Phase I/II trial of multicycle high-dose chemotherapy with peripheral blood stem cell support for treatment of advanced ovarian cancer. |
| Q36443934 | Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009. |
| Q87440391 | Phase II study of interval debulking surgery followed by intraperitoneal chemotherapy for advanced ovarian cancer: a Kansai Clinical Oncology Group study (KCOG9812) |
| Q33160644 | Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer |
| Q45928405 | Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. |
| Q47993999 | Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer |
| Q33395748 | Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer |
| Q91592033 | Phase III trials in ovarian cancer: The evolving landscape of front line therapy |
| Q34628651 | Phase ii/iii study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: ncic ctg ov.21. |
| Q40370693 | Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer |
| Q33612006 | Photo-cross-linking of XPC-Rad23B to cisplatin-damaged DNA reveals contacts with both strands of the DNA duplex and spans the DNA adduct |
| Q36790826 | Photoimmunotherapy and irradiance modulation reduce chemotherapy cycles and toxicity in a murine model for ovarian carcinomatosis: perspective and results. |
| Q37813074 | Physical Activity and Gynecologic Cancer Survivorship |
| Q61848136 | Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver |
| Q46554935 | Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer--a study by the OVCAD consortium. |
| Q37314520 | Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer |
| Q47963833 | Population pharmacokinetics and dosing recommendations for cisplatin during intraperitoneal peroperative administration: development of a limited sampling strategy for toxicity risk assessment |
| Q26822458 | Ports and complications for intraperitoneal chemotherapy delivery |
| Q39417613 | Post-traumatic Stress Disorder in patients with ovarian cancer |
| Q35766191 | Potent therapeutic activity of folate receptor-targeted liposomal carboplatin in the localized treatment of intraperitoneally grown human ovarian tumor xenograft |
| Q49593669 | Potential microRNA-related Targets for Therapeutic Intervention with Ovarian Cancer Metastasis |
| Q38258602 | Potential nanotechnologies and molecular targets in the quest for efficient chemotherapy in ovarian cancer |
| Q90190843 | Potential survival benefits from optimized chemotherapy implementation in advanced ovarian cancer: Projections from a microsimulation model |
| Q35076260 | Practical considerations in ovarian cancer chemotherapy |
| Q96297778 | Practical guidelines for triage to neoadjuvant chemotherapy in advanced ovarian cancer: Big risk, big reward…or too much risk? |
| Q39983001 | Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer |
| Q90317640 | Pre-operative Circulating Plasma Gelsolin Predicts Residual Disease and Detects Early Stage Ovarian Cancer |
| Q30419554 | Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study |
| Q37644866 | Preclinical activity of melflufen (J1) in ovarian cancer |
| Q90754497 | Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer |
| Q43685297 | Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer |
| Q34636703 | Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer |
| Q92617897 | Preoperative intraperitoneal oxaliplatin for unresectable peritoneal carcinomatosis of colorectal origin: a pilot study |
| Q35605264 | Preparation and biodistribution of 188Re-labeled folate conjugated human serum albumin magnetic cisplatin nanoparticles (188Re-folate-CDDP/HSA MNPs) in vivo |
| Q91572974 | Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications |
| Q38253577 | Pressurized intraperitoneal chemotherapy (PIPAC) in women with gynecologic malignancies: a review |
| Q38322144 | Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma |
| Q38260301 | Primary debulking surgery for advanced ovarian cancer: are you a believer or a dissenter? |
| Q36791086 | Primary extraosseous Ewing sarcoma of the lung in children |
| Q37937935 | Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer |
| Q38126548 | Principle and evolving role of intraperitoneal chemotherapy in ovarian cancer |
| Q36004735 | Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer |
| Q27011840 | Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer |
| Q37735208 | Profound sensorineural hearing loss after one cycle of intraperitoneal cisplatin in treatment of advanced ovarian cancer. |
| Q40100306 | Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment: results of long-term follow-up |
| Q30359038 | Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. |
| Q44896901 | Prognostic information derived from RT-PCR analysis of peritoneal fluid in gastric cancer patients: results from a prospective multicenter clinical trial |
| Q34552079 | Prognostic significance of B-cells and pSTAT3 in patients with ovarian cancer |
| Q36244076 | Prognostic significance of the mitochondrial scoring system in ovarian cancer |
| Q35533363 | Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer. |
| Q36979840 | Progress in gynecologic cancer research: the Gynecologic Oncology Group experience |
| Q48794449 | Progress in the management of primary and recurrent ovarian carcinomatosis with peritonectomy procedure and HIPEC in a high volume centre |
| Q57975538 | Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer |
| Q58799481 | Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis |
| Q33931049 | Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases |
| Q42700731 | Protein-coding genes, long non-coding RNAs combined with microRNAs as a novel clinical multi-dimension transcriptome signature to predict prognosis in ovarian cancer |
| Q34126627 | Proteomics and ovarian cancer: integrating proteomics information into clinical care |
| Q36630481 | Publicly funded clinical trials and the future of cancer care |
| Q60919534 | Puerarin Relieves Paclitaxel-Induced Neuropathic Pain: The Role of Na1.8 β1 Subunit of Sensory Neurons |
| Q36679733 | Quality of life considerations in gynecologic cancer. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer |
| Q36689828 | Quality of life for patients with epithelial ovarian cancer |
| Q38661788 | Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study |
| Q47657613 | Quality-of-Life Evaluation After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy |
| Q37049160 | Quality-of-life issues in the management of epithelial ovarian cancer |
| Q35836336 | Quantifying and Reducing Uncertainties in Cancer Therapy |
| Q37368932 | Quantitative X-ray computed tomography peritoneography in malignant peritoneal mesothelioma patients receiving intraperitoneal chemotherapy |
| Q52388109 | RNA-Peptide nanoplexes drug DNA damage pathways in high-grade serous ovarian tumors. |
| Q35695164 | Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials |
| Q35750271 | Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer |
| Q38364615 | Radical surgery in ovarian cancer |
| Q38096059 | Radioimmunotherapy for peritoneal cancers |
| Q90013692 | Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study |
| Q92306380 | Rational combinations of immunotherapy with radiotherapy in ovarian cancer |
| Q46578002 | Rationale and study protocol for the Patient-Centered Outcome Aid (PCOA) randomized controlled trial: A personalized decision tool for newly diagnosed ovarian cancer patients |
| Q51231622 | Re: intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. |
| Q37620476 | Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer. |
| Q37997512 | Recent advances in drug delivery strategies for treatment of ovarian cancer |
| Q36286500 | Recent advances in systemic treatments for ovarian cancer |
| Q36628679 | Recent advances in the treatment of peritoneal dissemination of gastrointestinal cancers by nucleoside antimetabolites |
| Q37406816 | Recent perspectives of epithelial ovarian carcinoma |
| Q36622857 | Recent progress in the diagnosis and treatment of ovarian cancer |
| Q37861289 | Recent surgical management of ovarian cancer |
| Q35708197 | Recombinant viral protein promotes apoptosis and suppresses invasion of ovarian adenocarcinoma cells by targeting α5β1 integrin to down-regulate Akt and MMP-2 |
| Q37567848 | Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer |
| Q39739012 | Reducing excessive toxicity in ovarian cancer treatment: a personalized approach |
| Q39085518 | Reduction of CA125 Levels During Neoadjuvant Chemotherapy Can Predict Cytoreduction to No Visible Residual Disease in Patients with Advanced Epithelial Ovarian Cancer, Primary Carcinoma of Fallopian tube and Peritoneal Carcinoma |
| Q37553978 | Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management |
| Q52917228 | Regional hyperthermia of the abdomen in conjunction with chemotherapy for peritoneal carcinomatosis: evaluation of two annular-phased-array applicators. |
| Q39302770 | Regulatory considerations on endpoints in ovarian cancer drug development |
| Q35730375 | Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer |
| Q26768299 | Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes |
| Q64097833 | Resistance to paclitaxel is associated with a variant of the gene BCL2 in multiple tumor types |
| Q60683187 | Response and outcomes in elderly patients with stages IIIC–IV ovarian cancer receiving platinum–taxane chemotherapy |
| Q58691893 | Response of Cisplatin Resistant Skov-3 Cells to [Pt(-Acac)(γ-Acac)(DMS)] Treatment Revealed by a Metabolomic ¹H-NMR Study |
| Q36713156 | Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer |
| Q36088140 | Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform |
| Q46539686 | Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer |
| Q36112585 | Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study. |
| Q92533730 | Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date |
| Q34433546 | Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review) |
| Q42263964 | S-1 plus intravenous and intraperitoneal Paclitaxel for gastric cancer with peritoneal metastasis |
| Q37383301 | S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013. |
| Q34553508 | SEOM guideline in ovarian cancer 2014. |
| Q51815337 | SGO future forward: Our greatest challenges are our greatest opportunities. |
| Q45867119 | SPECT/CT imaging of baculovirus biodistribution in rat. |
| Q39553624 | Safety and Effectiveness of Percutaneously Inserted Peritoneal Ports Compared to Surgically Inserted Ports in a Retrospective Study of 87 Patients with Ovarian Carcinoma over a 10-Year Period |
| Q36851100 | Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis |
| Q31030585 | Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: a pilot study |
| Q37489450 | Salvage intraperitoneal chemotherapy for relapsed type II endometrial cancer: A pilot case-control study |
| Q38712794 | Scintigraphic peritoneography reveals a non-uniform (99m)Tc-Pertechnetat aerosol distribution pattern for Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) in a swine model |
| Q99583257 | Secondary and tertiary ovarian cancer recurrence: what is the best management? |
| Q47787815 | Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study. |
| Q33596742 | Secretory leukocyte protease inhibitor antagonizes paclitaxel in ovarian cancer cells |
| Q30900326 | Self-assembled micelles of amphiphilic PEGylated rapamycin for loading paclitaxel and resisting multidrug resistant cancer cells†Electronic supplementary information (ESI) available: Chemicals and reagents, detailed experimental procedures for mater |
| Q89223180 | Sentinel Lymph Node Biopsy for Cervical Cancer Patients - What's It Gonna Take? |
| Q38555716 | Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center. |
| Q90094950 | Severe hypertriglyceridemia during treatment with intraperitoneal cisplatin and paclitaxel for advanced stage fallopian tube carcinoma |
| Q92578667 | Shaping the standard of care in ovarian cancer management: A review of Gynecologic Oncology Group (GOG)/NRG oncology clinical trials of the past twenty years |
| Q38913984 | Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3β/β-catenin signalling |
| Q34263907 | Single compartment drug delivery |
| Q51307985 | Society of Gynecologic Oncology 2016 Annual Meeting: Highlights and context. |
| Q33940195 | Sodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC) |
| Q38106994 | Sorafenib for ovarian cancer |
| Q37245146 | Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer |
| Q58746833 | Splenectomy during cytoreductive surgery in epithelial ovarian cancer |
| Q93033966 | State of the science: Evolving role of surgery for the treatment of ovarian cancer |
| Q38464032 | Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer |
| Q38735577 | Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer |
| Q53813485 | Structural Characterization of Anticancer Drug Paclitaxel and Its Metabolites Using Ion Mobility Mass Spectrometry and Tandem Mass Spectrometry. |
| Q47597543 | Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings |
| Q64973847 | Surgery with curative intent for stage IV gastric cancer: Is it a reality of illusion? |
| Q83508202 | Surgical debulking of ovarian cancer: what difference does it make? |
| Q80212968 | Surgical management of peritoneal carcinomatosis: from clinical research to standard of care |
| Q53244872 | Surgical outcomes for gastric cancer patients with intraperitoneal free cancer cell, but no macroscopic peritoneal metastasis. |
| Q37798985 | Surgical treatment for peritoneal carcinomatosis from gastric cancer |
| Q38163913 | Surgical treatment of peritoneal carcinomatosis: current treatment modalities |
| Q58051872 | Survival Benefit of Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer: A Multi-institutional Case Control Study |
| Q30437190 | Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience |
| Q50795446 | Survival benefit of intravenous and intraperitoneal paclitaxel with S-1 in pancreatic ductal adenocarcinoma patients with peritoneal metastasis: a retrospective study in a single institution. |
| Q92432508 | Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study |
| Q34762831 | Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis |
| Q39816174 | Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. |
| Q34577012 | Survival outcomes and toxicity of intraoperative intraperitoneal chemotherapy in advanced epithelial ovarian cancer |
| Q37036784 | Survivorship as an element of clinical trials in ovarian cancer |
| Q52606027 | Synthesis of poly(1,2-glycerol carbonate)-paclitaxel conjugates and their utility as a single high-dose replacement for multi-dose treatment regimens in peritoneal cancer. |
| Q34629897 | Systematic review of intraperitoneal chemotherapy for gastric cancer |
| Q37779034 | Systematic review on the efficacy of multimodal treatment of sarcomatosis with cytoreduction and intraperitoneal chemotherapy |
| Q64058293 | Tailoring Ovarian Cancer Treatment: Implications of Mutations |
| Q37795802 | Targeted Agents in Ovarian Cancer |
| Q36579751 | Targeted and controlled anticancer drug delivery and release with magnetoelectric nanoparticles |
| Q36395811 | Targeted delivery of platinum-taxane combination therapy in ovarian cancer |
| Q26828581 | Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review |
| Q31149698 | Targeted methylation of the epithelial cell adhesion molecule (EpCAM) promoter to silence its expression in ovarian cancer cells |
| Q82680680 | Targeted therapy in gynecologic oncology: biology, strategy, and assessment |
| Q63359576 | Targeted therapy in ovarian cancer |
| Q41607677 | Targeted therapy of ovarian cancer including immune check point inhibitor |
| Q36378255 | Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy |
| Q37326414 | Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer |
| Q38731251 | Targeting of p32 in peritoneal carcinomatosis with intraperitoneal linTT1 peptide-guided pro-apoptotic nanoparticles. |
| Q37082789 | Targeting signaling pathways in ovarian cancer. |
| Q34504817 | Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974. |
| Q37086007 | Taxanes in the management of gynecologic malignancies |
| Q37692801 | Taxanes: their impact on gynecologic malignancy |
| Q37444787 | Taxol-oligoarginine conjugates overcome drug resistance in-vitro in human ovarian carcinoma |
| Q40507435 | The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score. |
| Q91856102 | The Chicago Consensus on peritoneal surface malignancies: Management of ovarian neoplasms |
| Q36063233 | The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer |
| Q38715211 | The Role of the Immune System in Ovarian Cancer and Implications on Therapy |
| Q55220517 | The Role of the Insulin-Like Growth Factor 1 Pathway in Immune Tumor Microenvironment and Its Clinical Ramifications in Gynecologic Malignancies. |
| Q57823598 | The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer |
| Q39674041 | The antitumor effect of a thermosensitive polymeric hydrogel containing paclitaxel in a peritoneal carcinomatosis model. |
| Q30422170 | The association between quality of life domains and overall survival in ovarian cancer patients during adjuvant chemotherapy: a Gynecologic Oncology Group Study |
| Q33622369 | The biology of ovarian cancer: new opportunities for translation |
| Q36623372 | The current treatment of recurrent ovarian cancer |
| Q21198791 | The detection, treatment, and biology of epithelial ovarian cancer |
| Q37813173 | The diagnostic and molecular characteristics of malignant mesothelioma and ovarian/peritoneal serous carcinoma |
| Q42871376 | The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer |
| Q35647075 | The effect of neighborhood-level socioeconomic status on racial differences in ovarian cancer treatment in a population-based analysis in Chicago |
| Q36830674 | The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum |
| Q47134449 | The efficacy of combination treatment of gabapentin and electro-acupuncture on paclitaxel-induced neuropathic pain |
| Q36903804 | The emerging role of molecular imaging and targeted therapeutics in peritoneal carcinomatosis |
| Q28290511 | The evolving role of catumaxomab in gastric cancer |
| Q91174411 | The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance |
| Q33419382 | The feasibility of administering varying high-dose consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of ovarian carcinoma |
| Q37636787 | The gain and loss of long noncoding RNA associated-competing endogenous RNAs in prostate cancer |
| Q39327701 | The generalizability of NCI-sponsored clinical trials accrual among women with gynecologic malignancies |
| Q81586923 | The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer |
| Q30418957 | The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study |
| Q84623190 | The impact of hospital type on the efficacy of chemotherapy treatment in ovarian cancer patients |
| Q87399723 | The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer |
| Q50168618 | The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas |
| Q90346249 | The limits of aggressive surgical cytoreduction |
| Q38535374 | The next steps in improving the outcomes of advanced ovarian cancer. |
| Q81478901 | The number of metastatic lymph nodes is a significant risk factor for bone metastasis and poor outcome after surgery for linitis plastica-type gastric carcinoma |
| Q36791216 | The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review |
| Q34399879 | The potential and hurdles of targeted alpha therapy - clinical trials and beyond. |
| Q38144166 | The potential of sunitinib as a therapy in ovarian cancer |
| Q35094175 | The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma |
| Q30405874 | The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study. |
| Q37148143 | The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study |
| Q36019903 | The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity |
| Q81746514 | The remarkable "paclitaxel story": how many chapters remain to be written? |
| Q34649255 | The resurgence of platinum-based cancer chemotherapy |
| Q36758929 | The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review. |
| Q38131754 | The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse. |
| Q84910382 | The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer |
| Q37788967 | The role of in vitro directed chemotherapy in epithelial ovarian cancer |
| Q28067698 | The role of surgery in advanced epithelial ovarian cancer |
| Q37832930 | The role of surgery in the management of epithelial ovarian cancer |
| Q33659166 | The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer |
| Q37496947 | The timing of caffeic acid treatment with cisplatin determines sensitization or resistance of ovarian carcinoma cell lines |
| Q24629295 | The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial |
| Q35845484 | Therapeutic strategies in epithelial ovarian cancer |
| Q36855062 | Therapy operating characteristic curves: tools for precision chemotherapy |
| Q35886086 | Three ongoing intraperitoneal chemotherapy trials in ovarian cancer |
| Q33371765 | Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen |
| Q36916874 | Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling |
| Q35583734 | Tolerability, Efficacy, and Safety of Pegylated Liposomal Doxorubicin in Combination with Carboplatin Versus Gemcitabine–Carboplatin for the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review |
| Q83656036 | Towards randomized trials of cytoreductive surgery using peritonectomy and hyperthermic intraperitoneal chemotherapy for ovarian cancer peritoneal carcinomatosis |
| Q36967173 | Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer. |
| Q36104314 | Transcatheter intraarterial therapies: rationale and overview |
| Q33880468 | Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies |
| Q53235678 | Treatment guidelines in ovarian cancer. |
| Q38275362 | Treatment of ovarian cancer in the older woman |
| Q53571926 | Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. |
| Q55318427 | Treatment of patients with peritoneal metastases from gastric cancer. |
| Q36987501 | Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals |
| Q26744031 | Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectives |
| Q35792998 | Trends in relative survival for ovarian cancer from 1975 to 2011. |
| Q33703133 | Tumor Penetrating Theranostic Nanoparticles for Enhancement of Targeted and Image-guided Drug Delivery into Peritoneal Tumors following Intraperitoneal Delivery |
| Q36607749 | Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model |
| Q37714442 | Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors |
| Q37415227 | Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer |
| Q91341197 | Tumour-reactive T cell subsets in the microenvironment of ovarian cancer |
| Q49874891 | Two protein-coding genes act as a novel clinical signature to predict prognosis in patients with ovarian serous cystadenocarcinoma |
| Q35832351 | Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer |
| Q80671889 | Update in the management of ovarian and cervical carcinoma |
| Q36571743 | Update on first-line treatment of advanced ovarian carcinoma |
| Q91770393 | Upfront citorreduction and hyperthermic intraperitoneal chemotherapy with paclitaxel in patients with stage III-C serous epithelial ovarian cancer |
| Q27021915 | Upper abdominal cytoreduction and thoracoscopy for advanced epithelial ovarian cancer: unanswered questions and the impact on treatment |
| Q37451733 | Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy |
| Q36011137 | Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer |
| Q33816983 | Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer |
| Q39267742 | Use of 5-Fluorouracil Loaded Micelles and Cisplatin in Thermosensitive Chitosan Hydrogel as an Efficient Therapy against Colorectal Peritoneal Carcinomatosis |
| Q37174938 | Use of antibodies and immunoconjugates for the therapy of more accessible cancers |
| Q33416610 | Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy |
| Q36932625 | Utilization and Toxicity of Alternative Delivery Methods of Adjuvant Chemotherapy for Ovarian Cancer |
| Q88755853 | Utilization of an Alternative Docetaxel-based Intraperitoneal Chemotherapy Regimen in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: A Continued Need for Ovarian Cancer Patients |
| Q40105132 | Utilization of intraperitoneal chemotherapy for optimally cytoreduced advanced stage epithelial ovarian cancer: A 10-year single institution experience with a racially diverse urban population. |
| Q35921697 | Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer |
| Q79409750 | Vaginal evisceration during intraperitoneal chemotherapy for advanced ovarian cancer |
| Q30439300 | Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort: a Gynecologic Oncology Group study |
| Q36608502 | Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival |
| Q47148453 | Variability in the therapeutic management of advanced ovarian cancer patients: a five-country survey of oncologists |
| Q90342385 | Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer |
| Q85195661 | Ventral hernia following primary laparotomy for ovarian, fallopian tube, and primary peritoneal cancers |
| Q27687617 | Versatility of Particulate Carriers: Development of Pharmacodynamically Optimized Drug-Loaded Microparticles for Treatment of Peritoneal Cancer |
| Q40036993 | Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. |
| Q34806920 | Water-dispersed single-wall carbon nanohorns as drug carriers for local cancer chemotherapy. |
| Q37598652 | Web-based symptom management for women with recurrent ovarian cancer: a pilot randomized controlled trial of the WRITE Symptoms intervention |
| Q91645432 | Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer |
| Q33409066 | Weekly carboplatin with paclitaxel compared to standard three-weekly treatment in advanced epithelial ovarian carcinoma--a retrospective study |
| Q34541427 | Weekly paclitaxel in ovarian cancer-the latest success story |
| Q35751371 | Well-defined single polymer nanoparticles for the antibody-targeted delivery of chemotherapeutic agents. |
| Q36484029 | What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? |
| Q38529445 | Why have ovarian cancer mortality rates declined? Part II. Case-fatality |
| Q80698928 | Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials |
| Q90721202 | Wnt Signaling in Ovarian Cancer Stemness, EMT, and Therapy Resistance |
| Q83393453 | [Rationale for perioperative chemotherapy treatment in peritoneal carcinomatosis] |
| Q87232786 | [Surgical options in cancer of unknown primary (CUP)] |
| Q89424650 | [Surgical treatment of peritoneal metastases from gynecological primary tumors] |
| Q30319726 | [Systemic treatment of peritoneal metastases]. |
| Q62598254 | combinations of inert phenolato Ti(iv) complexes with clinically employed anticancer chemotherapy: synergy with oxaliplatin on colon cells |
| Q46505275 | iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes |
| Q58764425 | mTORC1/2 inhibition re-sensitizes platinum-resistant ovarian cancer by disrupting selective translation of DNA damage and survival mRNAs |
| Q42700737 | miR-150 enhances apoptotic and anti-tumor effects of paclitaxel in paclitaxel-resistant ovarian cancer cells by targeting Notch3 |
| Q38366731 | miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer |
| Q52670043 | miR‑377 targets CUL4A and regulates metastatic capability in ovarian cancer. |
| Q34327430 | siRNA delivery for the treatment of ovarian cancer |
Search more.